KRAS and non-small cell lung carcinoma: Given the fact that K-RAS pG12C mutation is most frequently observed in NSCLC and there is already an approved drug for this indication, we explored the transcriptomic profile of these tumors in order to identify immune genomic alterations with potential for clinical translation.